Wayne C Koff

Summary

Affiliation: International AIDS Vaccine Initiative
Country: USA

Publications

  1. doi request reprint Accelerating next-generation vaccine development for global disease prevention
    Wayne C Koff
    International AIDS Vaccine Initiative IAVI, New York, NY 10004, USA
    Science 340:1232910. 2013
  2. ncbi request reprint Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines
    Wayne C Koff
    Research and Development, International AIDS Vaccine Initiative, 125 Broad Street, New York, NY 10004, USA
    Vaccine 31:B204-8. 2013
  3. doi request reprint HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem
    Wayne C Koff
    International AIDS Vaccine Initiative, 125 Broad Street, New York, United States
    Vaccine 30:4310-5. 2012
  4. ncbi request reprint HIV vaccine design: insights from live attenuated SIV vaccines
    Wayne C Koff
    International AIDS Vaccine Initiative, New York, New York 10038, USA
    Nat Immunol 7:19-23. 2006
  5. ncbi request reprint AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope
    Emilio A Emini
    International AIDS Vaccine Initiative, New York, NY 10038, USA
    Science 304:1913-4. 2004
  6. pmc Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
    Melissa D Simek
    International AIDS Vaccine Initiative, New York, NY 10028, USA
    J Virol 83:7337-48. 2009
  7. ncbi request reprint HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  8. ncbi request reprint An AIDS vaccine: no time to give up
    Dennis R Burton
    Lancet 364:1938. 2004
  9. pmc Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
    David I Watkins
    Wisconsin National Primate Research Center, University of Wisconsin Madison, 1220 Capitol Court, Madison, Wisconsin 53715, USA
    Nat Med 14:617-21. 2008

Collaborators

Detail Information

Publications9

  1. doi request reprint Accelerating next-generation vaccine development for global disease prevention
    Wayne C Koff
    International AIDS Vaccine Initiative IAVI, New York, NY 10004, USA
    Science 340:1232910. 2013
    ....
  2. ncbi request reprint Accelerating the development of a safe and effective HIV vaccine: HIV vaccine case study for the Decade of Vaccines
    Wayne C Koff
    Research and Development, International AIDS Vaccine Initiative, 125 Broad Street, New York, NY 10004, USA
    Vaccine 31:B204-8. 2013
    ....
  3. doi request reprint HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem
    Wayne C Koff
    International AIDS Vaccine Initiative, 125 Broad Street, New York, United States
    Vaccine 30:4310-5. 2012
    ..This presentation will review the challenges and opportunities for development of vaccine candidates capable of eliciting broadly neutralizing antibodies against HIV...
  4. ncbi request reprint HIV vaccine design: insights from live attenuated SIV vaccines
    Wayne C Koff
    International AIDS Vaccine Initiative, New York, New York 10038, USA
    Nat Immunol 7:19-23. 2006
    ..Here, the strategies defining key components of the protective immune response elicited by these vaccines are discussed...
  5. ncbi request reprint AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope
    Emilio A Emini
    International AIDS Vaccine Initiative, New York, NY 10038, USA
    Science 304:1913-4. 2004
  6. pmc Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm
    Melissa D Simek
    International AIDS Vaccine Initiative, New York, NY 10028, USA
    J Virol 83:7337-48. 2009
    ..These elite neutralizers provide promising starting material for the isolation of broadly neutralizing monoclonal antibodies to assist in HIV-1 vaccine design...
  7. ncbi request reprint HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  8. ncbi request reprint An AIDS vaccine: no time to give up
    Dennis R Burton
    Lancet 364:1938. 2004
  9. pmc Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans
    David I Watkins
    Wisconsin National Primate Research Center, University of Wisconsin Madison, 1220 Capitol Court, Madison, Wisconsin 53715, USA
    Nat Med 14:617-21. 2008
    ..Vaccine designers must now develop T cell vaccine strategies that reduce viral load after heterologous challenge...